DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Duligotuzumab
Duligotuzumab
Deciphering Molecular Mechanisms and Prioritizing Therapeutic Targets in Cardio-Oncology
Tanibirumab (CUI C3490677) Add to Cart
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab
Randomized Phase II Study of Duligotuzumab (MEHD7945A) Vs
Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma Paul Gougis , Camille Moreau Bachelard, Maud Kamal, Hui K
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab Or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells
MEHD7945A) Vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study
A Study Comparing Acute Toxicities of Cetuximab and Cisplatin In
(INN) for Biological and Biotechnological Substances
Utilizing Immunopet to Measure Tumor Response to Treatment in Breast Cancer
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma Paul Gougis , Camille Moreau Bachelard, Maud Kamal, Hui K
Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer
6.6.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
DARPP-32 Promotes ERBB3-Mediated Resistance to Molecular Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma
Top View
Downloaded from the Cbio Portal (
An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
Phase II Study of the Dual EGFR/HER3 Inhibitor
One for Treatment of Solid Cancers
Phase II Study of the Dual EGFR/HER3 Inhibitor
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Colorectal Cancer: from Genetic Landscape to Targeted Therapy
Phase II Study of the Dual EGFR/HER3 Inhibitor
Phase Ib Study Evaluating Safety and Clinical Activity Of
HER3 Signaling and Targeted Therapy in Cancer
Combined Blockade of MEK and PI3KCA As an Effective Antitumor
Imaging EGFR and HER3 Through 89Zr-Labeled MEHD7945A (Duligotuzumab) Received: 19 March 2018 Brooke N
(INN) for Biological and Biotechnological Substances
Randomized Phase II Study of Duligotuzumab + FOLFIRI Vs Cetuximab + FOLFIRI in 2Nd-Line Patients with KRAS Wild-Type Metastatic Colorectal Cancer
Cetuximab PET Delineated Changes in Cellular Distribution of EGFR Upon Dasatinib Treatment in Triple Negative Breast Cancer Brooke N
Antibodies Targeting Closely Adjacent Or Minimally Overlapping Epitopes Can Displace One Another
Thesis (PDF, 14.95MB)
Rna Containing Composition for Treatment of Tumor Diseases
Comprehensive Review of Targeted Therapy for Colorectal Cancer
PDF Download
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Phase Ib Study Evaluating Safety and Clinical Activity of the Anti-HER3